MDGL — Madrigal Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $10.62bn
- $10.13bn
- $958.40m
Brief: Madrigal Pharmaceuticals Announces Company Founder Rebecca Taub, M.D. To Become Senior Scientific And Medical Advisor David Soergel, M.D., Appointed Chief Medical Officer
Brief: Madrigal appoints Jacqualyn Fouse to its board
U.S. RESEARCH ROUNDUP-Abbvie, Freeport-Mcmoran, Goldman Sachs
U.S. STOCKS ON THE MOVE-AerCap Holdings, Salesforce, Emcor Group
Madrigal rises on robust sales and long-term data for liver disease drug
Madrigal Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Madrigal Announces Two-Year Data From The Compensated Mash Cirrhosis Arm Of The Maestro-Nafld-1 Trial
Brief: Madrigal Pharmaceuticals Q4 EPS USD -2.71
Sagimet rises as Oppenheimer initiates coverage with 'outperform'
U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target
Brief: RTW Investments Reports 9.2% Passive Stake In Madrigal Pharmaceuticals As Of Sept 30, 2024
U.S. RESEARCH ROUNDUP-Cigna, Marriott, Ralph Lauren
Madrigal Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary
Madrigal jumps after Q3 sales for fatty liver drug beats estimates
Brief: Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results
Brief: Madrigal Pharmaceuticals Q3 EPS USD -4.92
U.S. RESEARCH ROUNDUP-BXP, Medpace Holdings, Starbucks
Brief: Madrigal Pharmaceuticals Completes Enrollment Of Clinical Outcomes Study Of Resmetirom In Patients With Compensated Nash/Mash Cirrhosis
Brief: Madrigal Pharmaceuticals Publishes Positive Results From Phase 3 Maestro-Nash Trial Of Rezdiffra